MyFinsight
Home
About
Contact
lixt: the income statement
Download
Download image
Net loss
attributable to common...
-$2,030,765
Series b convertible
preferred stock 8...
-$50,367
Net loss
-$1,980,398
(-100.85%↓ Y/Y)
Interest income
$4,430
(208.28%↑ Y/Y)
Realized gain (loss) on
foreign currency...
-$130
Unrealized gain (loss) on
digital assets
-$182,887
Interest expense
$457
(-56.43%↓ Y/Y)
Loss from operations
-$1,801,354
(-83.20%↓ Y/Y)
Total costs and
expenses
$1,801,354
(83.20%↑ Y/Y)
General and
administrative costs
$1,750,658
(518.49%↑ Y/Y)
Research and development
costs
$50,696
(-85.98%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)